Sign in

SHPH on Nasdaq

Shuttle Pharmaceuticals Holdings, Inc.

Shuttle Pharmaceuticals Holdings, Inc. is an American pharmaceutical preparations company based in Gaithersburg.1 Its shares trade on Nasdaq under the symbol SHPH.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerSHPH on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersGaithersburg, Maryland1
  • Incorporated inDE2
  • Business address401 Professional Drive, Suite 260, Gaithersburg, Md 208792
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income3456-$11.9M in 2025+584% since 2021
-$15.0M-$10.0M-$5.0M02021: -$1.7M-$1.7M20212022: -$2.3M-$2.3M2022+34%2023: -$5.9M-$5.9M2023+151%2024: -$7.7M-$7.7M2024+31%2025: -$11.9M-$11.9M2025+55%
Net income3456-$11.7M in 2025+917% since 2021
-$15.0M-$10.0M-$5.0M02021: -$1.2M-$1.2M20212022: -$5.0M-$5.0M2022+334%2023: -$6.6M-$6.6M2023+32%2024: -$9.1M-$9.1M2024+39%2025: -$11.7M-$11.7M2025+28%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Research and development$4.1M$3.6M
General and administrative$5.7M$1.4M
Legal and professional$2.2M$2.7M
Total operating expenses$11.9M$7.7M
Net loss from operations-$11.9M-$7.7M
Interest income$1.1K$38.1K
Convertible notes finance fee-$152.7K
Change in fair value of derivative liabilities-$74.4K$555.8K
Change in fair value of convertible notes-$3.4K$122.6K
Gain on sale of marketable securities$28.6K
Gain on settlement of debt$342.6K
Loss on settlement of convertible debt-$833.5K
Total other (expense) income$195.2K-$1.4M
Net loss-$11.7M-$9.1M
Weighted average common shares outstanding - basic1.6M shares114.8K shares
Net loss per shares - basic-$7.16-$79.65
Weighted average common shares outstanding - diluted1.6M shares115.5K shares
Net loss per share - diluted-$7.16-$82.60

Compare Shuttle Pharmaceuticals Holdings, Inc. with another company

Corporate structure

Shuttle Pharmaceuticals Holdings, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Shuttle Pharmaceuticals Holdings, Inc.

  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on Shuttle Pharmaceuticals Holdings, Inc., latest Aug 14, 2025 (3 filings since Feb 14, 2025)
  • AFH Holding & Advisory, LLC Filed SC 13G/A on Shuttle Pharmaceuticals Holdings, Inc., latest Oct 18, 2023 (3 filings since Mar 6, 2023)
  • Shuttle Pharmaceuticals Holdings, Inc. Gaithersburg, Maryland

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Shuttle Pharmaceuticals Holdings, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$17.3K6 Dec 31, 2025$19.4K6 Dec 31, 2024−10.6%
Operating-lease assets (leased space)$102.4K6 Dec 31, 2025$276.0K6 Dec 31, 2024−62.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$334.0K6 Dec 31, 2025$1.9M6 Dec 31, 2024−82.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$9.8M6 Dec 31, 2025
Finite-lived intangibles, net$9.8M6 Dec 31, 2025

Properties, in its own words

Facilities

Our corporate headquarters are presently located in 401 Professional Drive, Suite 260, Gaithersburg, Maryland 20879 where we lease approximately 2,109 square feet of office and laboratory space (together, the “Laboratory Space”), which includes shared access to office space and reception services. We entered into a lease for the new Laboratory Space on June 1, 2023, and the lease has an initial term of 5.25 years and an option to extend for an additional three years, with a monthly rent of $7,206 per month, subject to increase at the rate of 3% per year. All of such space is leased from a non-affiliated third party. We believe that the above facilities are adequate for our current needs.

Item 2 of the 10-K filed Mar 31, 2026.9

Leadership

Who has led Shuttle Pharmaceuticals Holdings, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Anatoly Dritschilo2022–2023
  2. Chris Cooper2025–2026
  3. Ryan Trasolini2026–now

Chair

  1. Anatoly Dritschilo2022–2023

President

  1. Peter Dritschilo2022

Chief financial officer

  1. Hoek Michael Vander2022–2024
  2. Timothy J. Lorber2024–2026
  3. Yuying Liang2026–now

Chief operating officer

  1. Peter Dritschilo2022
2025
Board members and other officers (14)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Vice President - Operations and RegulatoryMichael Vander Hoek named Jan 4, 2022 to Oct 25, 202431
  • President and Chief Operating OfficerPeter Dritschillo named Feb 22, 2022 to Aug 15, 202232
  • DirectorSachin Pathigoda named Nov 7, 202533
  • DirectorGeorge Scorcis named Jun 26, 202534

Timeline

  1. Sep 24, 20268-K Financial statements and exhibits35
  2. Sep 16, 20268-K Unregistered sale of shares36
  3. Sep 11, 20268-K Shareholder vote37
  4. Sep 2, 20268-K Other events38
  5. Sep 1, 20268-K Entered a material agreement39
  6. Aug 28, 20268-K Listing notice or transfer; Regulation FD disclosure40
  7. Aug 17, 20268-K Completed an acquisition or sale41
  8. Jul 1, 20268-K Regulation FD disclosure; Other events42
  9. Jun 11, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed43
  10. Jun 1, 2026New chief executive Ryan Trasolini becomes CEO10
  11. May 27, 20268-K Shareholder vote44
  12. May 7, 20268-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares45
  13. May 1, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure46
  14. Apr 2, 2025New chief executive Chris Cooper becomes CEO11
  15. Sep 7, 2022New chief executive Anatoly Dritschilo becomes CEO12

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/202647

When it reported results

  1. Feb 17, 2026Reported quarterly or annual results48
  2. Feb 26, 2025Reported quarterly or annual results49
  3. Nov 13, 2024Reported quarterly or annual results50
  4. May 14, 2024Reported quarterly or annual results51
  5. Mar 22, 2024Reported quarterly or annual results52
  6. Nov 14, 2023Reported quarterly or annual results53
  7. Aug 15, 2023Reported quarterly or annual results54
  8. May 26, 2023Reported quarterly or annual results55

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

304 filings to the SEC since October 2021: 5 annual reports, 13 quarterly reports, 101 major events, 56 insider forms, 6 large holders, 8 private raises, 115 other. The latest 20:

  1. Sep 24, 202610-Q EDGAR
  2. Sep 24, 20268-K/A EDGAR
  3. Sep 16, 20268-K EDGAR
  4. Sep 11, 20268-K EDGAR
  5. Sep 2, 2026DEFA14A EDGAR
  6. Sep 2, 20268-K EDGAR
  7. Sep 1, 20268-K EDGAR
  8. Aug 28, 20268-K EDGAR
  9. Aug 17, 2026NT 10-Q EDGAR
  10. Aug 17, 20268-K/A EDGAR
  11. Aug 13, 2026DEFA14A EDGAR
  12. Aug 13, 2026DEF 14A EDGAR
  13. Aug 3, 2026PRE 14A EDGAR
  14. Jul 15, 20264 PRIMARY DOCUMENT EDGAR
  15. Jul 13, 20264 PRIMARY DOCUMENT EDGAR
  16. Jul 13, 20263 PRIMARY DOCUMENT EDGAR
  17. Jul 9, 20264 PRIMARY DOCUMENT EDGAR
  18. Jul 7, 20264 PRIMARY DOCUMENT EDGAR
  19. Jul 2, 20264 PRIMARY DOCUMENT EDGAR
  20. Jul 1, 20268-K EDGAR

The 304 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

23 open-market trades by officers, directors and large owners since October 2021: 6 buys and 17 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 14, 2026HRT FINANCIAL LP10% ownerSale82,116$4.48$367.9KForm 4
Jul 13, 2026HRT FINANCIAL LP10% ownerSale1,033$4.67$4.8KForm 4
Jul 10, 2026HRT FINANCIAL LP10% ownerBuy731$3.11$2.3KForm 4
Jul 9, 2026HRT FINANCIAL LP10% ownerBuy8,266$3.38$27.9KForm 4
Jul 8, 2026HRT FINANCIAL LP10% ownerSale18,531$3.52$65.2KForm 4
Jul 7, 2026HRT FINANCIAL LP10% ownerSale10,580$3.33$35.2KForm 4
Jul 6, 2026HRT FINANCIAL LP10% ownerSale9,022$3.51$31.7KForm 4
Jul 2, 2026HRT FINANCIAL LP10% ownerBuy7,851$3.54$27.8KForm 4
Jul 1, 2026HRT FINANCIAL LP10% ownerBuy3,959$3.30$13.1KForm 4
Jun 30, 2026HRT FINANCIAL LP10% ownerBuy6,755$3.23$21.8KForm 4
Jun 29, 2026HRT FINANCIAL LP10% ownerBuy25,836$3.44$88.9KForm 4
Dec 13, 2023Brown MiltonDirectorSale2,921$0.46$1.3KForm 4
Dec 13, 2023Jacobs BetteDirectorSale4,157$0.46$1.9KForm 4
Dec 29, 2022Senanayake ChrisDirectorSale1,626$1.61$2.6KForm 4
Dec 29, 2022Richards Steven MDirectorSale995$1.61$1.6KForm 4
Dec 29, 2022Adkins WilliamSale995$1.61$1.6KForm 4
Dec 29, 2022Brown MiltonDirectorSale995$1.61$1.6KForm 4
Dec 29, 2022Dritschilo AnatolyCEO and ChairmanSale8,372$1.61$13.5KForm 4
Dec 29, 2022Rich TyvinChief Medical OfficerSale1,414$1.61$2.3KForm 4
Dec 29, 2022Jung MiraChief Scientific OfficerSale328$1.61$528Form 4

All 23 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$22.5M 2021–2026
Money received by yearMoney received by year, 2021–2026: $22.5M in all. Private raises (Form D) $22.5M.$0$2.5M$5M$7.5M$10M2021 · Private raises (Form D): $500.0K20212022 · Private raises (Form D): $490.0K2023 · Private raises (Form D): $4.0M20232024 · Private raises (Form D): $790.0K2025 · Private raises (Form D): $6.7M20252026 · Private raises (Form D): $10.0M2026
Figures by year
YearPrivate raises (Form D)Total
2026$10.0M$10.0M
2025$6.7M$6.7M
2024$790.0K$790.0K
2023$4.0M$4.0M
2022$490.0K$490.0K
2021$500.0K$500.0K

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Apr 30, 2026Raised $10 million in a private offering of equity58 Form D: 47 investors so far Form D
  2. Nov 3, 2025Raised $2.5 million in a private offering of securities33 Form D: $2.5 million offered in all Form D
  3. Jun 20, 2025Raised $4.2 million in a private offering of equity34 Form D: 1 investor so far Form D
  4. Oct 14, 2024Raised $790,000 in a private offering of securities31 Form D: $1.3 million offered in all Form D
  5. Jan 11, 2023Raised $4 million in a private offering of securities59 Form D: 1 investor so far Form D
  6. Aug 1, 2022Raised $125,000 in a private offering of debt32 Form D: $500,000 offered in all Form D
  7. Feb 8, 2022Raised $365,000 in a private offering of debt60 Form D: $2 million offered in all Form D
  8. Dec 28, 2021Raised $500,000 in a private offering of debt61 Form D: 2 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Citadel Advisors LLC24,354$79.2K0.0%New
Barclays PLC750$2.4K0.0%New
Tower Research Capital LLC (TRC)389$1.3K0.0%New
Kelleher Financial Advisors120$3900.0%New
Hrt Financial LP78,597$2550.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Shuttle Pharmaceuticals Holdings, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARShuttle Pharmaceuticals Holdings, Inc.1
  • CIK0001757499
  • Employer ID (EIN)82-50898269
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company9
  • Incorporated inDelaware9
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address401 Professional Drive, Suite 260, Gaithersburg, MD 208791
  • Phone(240) 403-42121
  • Shares outstanding4,764,696 as of Sep 21, 20268
  • Public float$4.7M as of Jun 30, 20259
  • AuditorForvis Mazars, LLP, Atlanta, Georgia PCAOB ID 686; no auditor attestation of internal control over financial reporting9
  • On EDGAR sinceJan 31, 20191
  • Filings306 in all: 8-K (99), 4 (27), 3 (23), CORRESP (20), UPLOAD (13), 10-Q (12), 424B3 (12), S-1/A (11)1
    All 39 form types

    D (9), S-1 (9), EFFECT (8), DEF 14A (7), 10-K (4), ARS (4), DRS/A (4), PRE 14A (4), 5 (3), DEFA14A (3), DRS (3), NT 10-Q (3), 424B4 (2), 5/A (2), 8-K/A (2), DEF 14C (2), DRSLTR (2), PRE 14C (2), PRER14A (2), SC 13G (2), SCHEDULE 13G/A (2), 10-K/A (1), 10-Q/A (1), 3/A (1), 8-A12B (1), CERT (1), DEFR14A (1), RW (1), S-8 (1), SC 13G/A (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Sep 24, 2026
    Proxy statement (DEF 14A) Aug 13, 2026
    Latest 8-K (8-K) Sep 16, 2026

Securities registered for trading

ClassSymbolExchange
Common StockSHPHThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).9

Risk factors and legal proceedings

The risks Shuttle Pharmaceuticals Holdings, Inc. names in Item 1A of its 10-K filed Mar 31, 2026: 19 risks under these headings, as written.9

  • Risks Related to Our Business, Financial Condition and Capital Requirements
  • Our consolidated financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business; our ability to continue as a going concern is dependent upon our ability to raise additional equity or debt financing to fund our operations.
  • Recent and future acquisitions may have a material adverse effect on our ability to manage our business and our results of operations and financial condition.
  • If we are unable to acquire and retain customers for our Molecule.ai platform or if any of such customers renew licenses at lower prices, our future revenues may be negatively impacted.
  • While our Company’s management is working to improve our internal controls and procedures, at present management has determined that our internal controls were deemed to be inadequate, which could cause our financial reporting to be unreliable and lead to misinformation being disseminated to the public.
  • Failure of our information technology systems could significantly disrupt the operation of our business.
  • Risks Related to our Common Stock
  • If we fail to comply with the continued listing requirements of The Nasdaq Stock Market, it could result in our common stock being delisted, which could adversely affect the market price and liquidity of our securities and could have other adverse effects.
  • Our stock price may be volatile, and purchasers of our common stock could incur substantial losses.
  • The future issuance of equity or of debt securities that are convertible into common stock will dilute our share capital.
  • If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.
  • Our board of directors has the authority, without stockholder approval, to issue preferred stock with terms that may not be beneficial to holders of our common stock and such issuance could potentially adversely affect stockholders’ voting power and perpetuate their control over us.
The other 9 risks
  • Our Certificate of Incorporation and Bylaws, each as amended to date, provide for indemnification of officers and directors at the expense of the Company and limit their liability that may result in a major cost to us and hurt the interests of our stockholders because corporate resources may be expended for the benefit of officers and/or directors.
  • Our Certificate of Incorporation, as amended to date, provides that disputes must be resolved in the Court of Chancery of the State of Delaware, except for cases brought under the Securities Act or Exchange Act.
  • We do not expect to pay cash dividends in the foreseeable future.
  • Provisions in our amended and restated certificate of incorporation, as amended, and bylaws, as amended, as well as Delaware law, might discourage, delay or prevent a change of control of our company or changes in our management and, therefore, depress the market price of our common stock.
  • Sales of substantial amounts of our securities in the public market could depress the market price of our common stock.
  • Although we have no preferred stock outstanding as of the date hereof and we have currently no intention to issue any preferred stock, our common stockholders could be adversely affected by the issuance by us of preferred stock in the future, if any.
  • Trading of our common stock may be limited, making it difficult for our stockholders to sell their shares, and future sales of common stock could reduce our stock price.
  • FINRA sales practice requirements may limit a stockholder’s ability to buy and sell our securities.
  • We are an emerging growth company and a smaller reporting company within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to emerging growth companies or smaller reporting companies, this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies.

Legal proceedings

Currently, there are no material legal proceedings pending or threatened against us. We are not presently party to any pending or other threatened legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results, although from time to time, we may become involved in legal proceedings in the ordinary course of business.

The opening of Item 3, Legal Proceedings.9

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
    SEC EDGAROther events
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61